Evaluating patient satisfaction and quality of life in Hidradenitis Suppurativa patients treated with Secukinumab.
Assessing Short-term Treatment Satisfaction and Quality of Life in Patients With Hidradenitis Suppurativa Initiated on Secukinumab in Routine Clinical Practice in the United Arab Emirates: ILLUMINATE-HS, a Prospective Patient Surve
This study is trying to see how happy and satisfied people with Hidradenitis Suppurativa feel after starting a new treatment called Secukinumab over 24 weeks.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 60 (estimated) |
| Ages | 18 Years to 99 Years |
| Sex | All |
| Sponsor | Novartis Industry-sponsored |
| Drugs / interventions | Secukinumab, Adalimumab |
| Locations | 1 site (Sharjah) |
| Trial ID | NCT06785675 on ClinicalTrials.gov |
What this trial studies
This observational study aims to gather data on the short-term treatment satisfaction and quality of life in patients with Hidradenitis Suppurativa who are newly initiated on Secukinumab. Over a 24-week period, patient-reported outcomes will be collected through questionnaires and electronic medical records to assess their experiences. The study focuses on a representative population in the Gulf Region, specifically the United Arab Emirates, to provide insights into real-world treatment effects.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with a confirmed diagnosis of moderate to severe Hidradenitis Suppurativa who are newly starting treatment with Secukinumab.
Not a fit: Patients who do not meet the inclusion criteria or refuse to participate will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into how Secukinumab improves the quality of life for patients with Hidradenitis Suppurativa.
How similar studies have performed: While this approach is focused on a specific population and treatment, similar studies have shown promise in evaluating patient-reported outcomes in chronic conditions.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient with a confirmed diagnosis of active moderate to severe HS (Hurley Score 2-3) * Male or Female adult patients ≥ 18 years of age at the time of data collection * Patient newly initiated on Secukinumab (first dose to coincide within 1 month of the signature of the informed consent) * Patients with a diagnosis of HS who are currently using antibiotics/ have undergone surgery or not as part of their routine clinical management are eligible for inclusion. * Patients with a diagnosis of HS who have a history of previous treatment with Adalimumab or any other anti-TNF agent as part of their routine clinical management or biologic naïve are eligible for inclusion. * Agreed to sign an informed consent to be able to fill in the questionnaires. Exclusion Criteria: * Patients not fulfilling any of the abovementioned inclusion criteria. * Patient's refusal to be included in the study or refusal to sign the informed consent.
Where this trial is running
Sharjah
- Novartis Investigative Site — Sharjah, United Arab Emirates (Recruiting)
Study contacts
- Study coordinator: Novartis Pharmaceuticals
- Email: novartis.email@novartis.com
- Phone: +41613241111
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.